Literature DB >> 3359561

Renal impairment following the combined use of high-dose methotrexate and procarbazine.

P Price1, H Thompson, E M Bessell, H J Bloom.   

Abstract

A major side-effect of high-dose methotrexate is renal toxicity, which may develop unexpectedly despite adequate standard precautions such as hydration and alkalinisation of the urine. The pathogenesis is unclear. Recent reports suggest that the combination of high-dose methotrexate with non-chemotherapeutic agents may cause such renal impairment. Three cases of unexpected renal impairment following the combined use of high-dose methotrexate and another cytotoxic agent, procarbazine, are reported. Possible mechanisms of this interaction are discussed, as are recommendations for future combined administration.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3359561     DOI: 10.1007/bf00262783

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  9 in total

1.  Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration.

Authors:  D D Von Hoff; J S Penta; L J Helman; M Slavik
Journal:  Cancer Treat Rep       Date:  1977-07

2.  Cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP) treatment of non-oat cell bronchogenic carcinoma.

Authors:  N J Vogelzang; P D Bonomi; A H Rossof; J Wolter
Journal:  Cancer Treat Rep       Date:  1978-10

3.  Effect of gentamicin and irradiation on the toxicity of high-dose methotrexate in rats.

Authors:  G B Spector; Y M Wang; C A Gleiser; R C Chan; J van Eys
Journal:  Cancer Treat Rep       Date:  1980 Aug-Sep

4.  Weekly methotrexate-calcium leucovorin rescue: effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-Hodgkin's lymphoma.

Authors:  S W Pitman; E Frei
Journal:  Cancer Treat Rep       Date:  1977-07

5.  Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen.

Authors:  A Thyss; G Milano; J Kubar; M Namer; M Schneider
Journal:  Lancet       Date:  1986-02-01       Impact factor: 79.321

6.  The effect of high-dose methotrexate on renal tubules as indicated by urinary lysozyme concentration.

Authors:  M Freeman-Narrod; J S Kim; H Ohanissian; K Mills; J W Smiley; I Djerassi
Journal:  Cancer       Date:  1982-12-15       Impact factor: 6.860

Review 7.  The clinical pharmacology of methotrexate: new applications of an old drug.

Authors:  W A Bleyer
Journal:  Cancer       Date:  1978-01       Impact factor: 6.860

8.  CCNU, vincristine, methotrexate, and procarbazine treatment of relapsed small cell lung carcinoma.

Authors:  E A Poplin; J Aisner; D A Van Echo; M Whitacre; P H Wiernik
Journal:  Cancer Treat Rep       Date:  1982-07

9.  Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine.

Authors:  H T Abelson; M T Fosburg; G P Beardsley; A M Goorin; C Gorka; M Link; D Link
Journal:  J Clin Oncol       Date:  1983-03       Impact factor: 44.544

  9 in total
  4 in total

1.  Renal and hepatic toxicity after high-dose 7-hydroxymethotrexate in the rat.

Authors:  E Smeland; R M Bremnes; A Andersen; R Jaeger; T J Eide; N E Huseby; J Aarbakke
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

2.  High-dose 7-hydromethotrexate: acute toxicity and lethality in a rat model.

Authors:  E Smeland; O M Fuskevåg; K Nymann; J S Svendesn; R Olsen; S Lindal; R M Bremnes; J Aarbakke
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

Review 3.  Anticancer drug-induced kidney disorders.

Authors:  P E Kintzel
Journal:  Drug Saf       Date:  2001-01       Impact factor: 5.228

4.  Quercetin, a Flavonoid Antioxidant, Ameliorated Procarbazine-Induced Oxidative Damage to Murine Tissues.

Authors:  Ebenezer Tunde Olayinka; Ayokanmi Ore; Oluwatobi Adewumi Adeyemo; Olaniyi Solomon Ola; Olaoluwa Oluwaseun Olotu; Roseline Chinonye Echebiri
Journal:  Antioxidants (Basel)       Date:  2015-04-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.